Macrophage-mediated activation of camptothecin analogue T-2513-carboxymethyl dextran conjugate (T-0128): possible cellular mechanism for antitumor activity.
Camptothecin (CPT) analogue T-2513-carboxymethyl (CM) dextran conjugate (T-0128) suppressed human tumor xenografts that were refractory to CPTs. This improvement was explained by its altered pharmacokinetics, but the cellular mechanism of action is still not clear. For this reason, in the present study we examined the determinants of T-0128 action at the cellular level. In vitro tests showed that T-0128 was inactive, indicating that the requirement for its activity lies in the release of linked T-2513, accompanied by the cellular uptake of the conjugate. The accumulation varied between cell lines: tumor cells, including Walker-256 carcinoma and B16 melanoma, showed only a marginal uptake and an undetectable drug release in the medium. In contrast, macrophage-like cells, such as J774.1, internalized T-0128 very efficiently, and liberated T-2513. With regard to the mode of accumulation, fluid-phase pinocytosis seems to be a key factor based on the followings: a similar cell-specificity existed in the uptake of FITC dextran, a marker of fluid-phase pinocytosis. Also, the macrophage uptake of T-0128 increased almost linearly with its medium concentration and was insensitive to dextran sulfate, a ligand for macrophage scavenger receptor. Comparative efficacy studies of T-0128 in the presence and absence of macrophages demonstrated that macrophages increased the efficacy of T-0128. The enhancement could be explained in terms of increases in the amount of released T-2513. Overall, these results lead us to the conclusion that T-0128 acts like a Trojan horse with the help of macrophages: T-0128 is taken up by macrophages in tumor tissues, and the liberated T-2513 kills tumor cells.
Harada
M
M
Discovery Research Laboratory, Tanabe Seiyaku Co. Ltd., Kashima 3-16-89, Yodogawa-ku, 532-8505, Osaka, Japan. m-harada@tanabe.co.jp
Imai
J
J
Okuno
S
S
Suzuki
T
T
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D001711:Biotransformation; D002460:Cell Line; D003911:Dextrans / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D008264:Macrophages / Q000378:metabolism*; D051379:Mice; D011355:Prodrugs / Q000494:pharmacology*; D019772:Topotecan / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology
D000972:Antineoplastic Agents, Phytogenic; D003911:Dextrans; D011355:Prodrugs; D019772:Topotecan; C410031:T 0128